To combat recent stock weakness, Botox-maker Allergan is resorting to the oldest trick in the book: share buybacks.
On Monday, it authorized a $2 billion repurchase of its common stock, employing a tactic frequently used by companies to boost shares during times devoid of other positive catalysts.
